Elisabetta Dejana Lab

Elisabetta Dejana

Elisabetta Dejana, a cell biologist and expert on regulation of vascular system development, directs the New strategies to inhibit tumor angiogenesis research unit at IFOM, which focuses on development of tumor vasculature.
After earning a degree in Biological Sciences from the University of Bologna, she moved to Milan to work at the Mario Negri Institute for Pharmacological Research, where she investigated the mechanisms underlying pathological thrombosis and cardiovascular diseases. read more

Contact the researcher

New strategies to inhibit tumor angiogenesis

One of the innovative aspects of anti-cancer therapies concerns the possibility of inhibiting tumor growth by blocking blood supply. The simple idea is that, if starved, the tumor will not grow but, on the contrary, will shrink and become more susceptible to chemotherapy and radiotherapy. Cancer cells induce the formation of their own vascular system by recruiting new vessels from the host. However, the resulting vasculature is structurally and functionally abnormal. read more

Laboratory location: Milan, Italy

Recent publications

Cottarelli A, Corada M, Beznoussenko GV, Mironov AA, Globisch MA, Biswas S, Huang H, Dimberg A, Magnusson PU, Agalliu D, Lampugnani MG, Dejana E.
Fgfbp1 promotes blood-brain barrier development by regulating collagen IV deposition and maintaining Wnt/β-catenin signaling.
Development. 2020 Aug 24;147(16):dev185140. doi: 10.1242/dev.185140. PMID: 32747434; PMCID: PMC7473640.
Kakogiannos N, Ferrari L, Giampietro C, Scalise AA, Maderna C, Ravà M, Taddei A, Lampugnani MG, Pisati F, Malinverno M, Martini E, Costa I, Lupia M, Cavallaro U, Beznoussenko GV, Mironov AA, Fernandes B, Rudini N, Dejana E, Giannotta M.
JAM-A Acts via C/EBP-α to Promote Claudin-5 Expression and Enhance Endothelial Barrier Function.
Circ Res. 2020 Sep 25;127(8):1056-1073. doi: 10.1161/CIRCRESAHA.120.316742. Epub 2020 Jul 15. PMID: 32673519; PMCID: PMC7508279.
Lanfranconi S, Scola E, Bertani GA, Zarino B, Pallini R, d'Alessandris G, Mazzon E, Marino S, Carriero MR, Scelzo E, Faragò G, Castori M, Fusco C, Petracca A, d'Agruma L, Tassi L, d'Orio P, Lampugnani MG, Nicolis EB, Vasamì A, Novelli D, Torri V, Meessen JMTA, Al-Shahi Salman R, Dejana E, Latini R; Treat- CCM Investigators.
Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial
Trials. 2020 May 12;21(1):401. doi: 10.1186/s13063-020-4202-x. PMID: 32398113; PMCID: PMC7218540.

complete list PubMed

Group members - IFOM

Technician

Maderna Claudio

Post Doc

Giannotta Monica

PhD Student

Scalise Anna Agata
Valentino Mariaelena

Former lab members

Stefan Liebner (Group Leader at Institute of Neurology, Johann Wolfgang Goethe-University Frankfurt, Germany)
Luigi Maddaluno (ETH, Zurich, Switzerland)
Daniel Nyqvist (Group Leader at Karolinska Insitutet, Stockholm, Sweden)
Andrea Taddei (Cancer Research UK, London)

(update: July 2022)